Development of a more effective and safer therapeutic antibody for cancer treatment with a dual mechanism of action to eliminate CSCs and reactivate the tumour’s immune system.

Project Information

CSC-IS

Grant agreement ID: 665671

DOI

10.3030/665671

Project closed

EC signature date 17 June 2015

Start date 1 July 2015

End date 31 December 2016

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost

€ 150 000,00

EU contribution

€ 150 000,00

Coordinated by

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)
Spain

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .